Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 14,953 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Clear all
Completed Phase 2 Interventional Results available

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

NCT05719311
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
adrulipase
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Orlando, Florida • Northfield, Illinois • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Acceptability and Efficacy of Zemedy App Versus Education and Relaxation Training App for IBS

NCT04665271
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Zemedy App
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT03765671
View directory record Official record
Conditions
Hepatic Impairment, Liver Disease, Pharmacokinetics
Interventions
Elafibranor
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 25, 2026, 6:15 AM EDT
Completed No phase listed Observational Results available

Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation

NCT04683744
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
Semi-structured interviews-Patients, Semi-structured interviews-Health system
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome

NCT00767364
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Biological
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
6 Weeks to 18 Months
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

NCT02057718
View directory record Official record
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
LUM001 (Maralixibat)
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

NCT03184870
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
BMS-813160, Nivolumab, Nab-paclitaxel, Gemcitabine, 5-fluorouracil (5-FU), Leucovorin, Irinotecan
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer

NCT02079220
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Arm A, Arm B
Drug
Lead sponsor
James J Lee
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 25, 2026, 6:15 AM EDT
Withdrawn Not applicable Interventional

Diagnostic Tests in Supra-Esophageal Gastroesophageal Reflux Disease (SE-GERD)

NCT05695846
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
externally applied cricoid cartilage pressure
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
20 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Not applicable Interventional

UC Cohort - The Influence of Diet on Gut Microbiotas

NCT04933162
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
High Protein and Low Fiber Diet, Low Protein and High Fiber Diet
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
Olvi-Vec, Platinum-doublet with or without bevacizumab
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Effect of Brief Dietary Intervention on Ammonia Levels

NCT05376488
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
One meal
Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

NCT03412773
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Tislelizumab, Sorafenib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT03650413
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 25, 2026, 6:15 AM EDT
Completed No phase listed Observational

Study of Transfusion-Transmitted Infections

NCT00023023
View directory record Official record
Conditions
Viral Disease, Blood Donation, Transfusion-Transmitted Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
1,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

NCT03146962
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Lung Cancer
Interventions
Vitamin C
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Monopolar and Bipolar Current RFA Knife in POEM

NCT05272046
View directory record Official record
Conditions
Esophageal Motility Disorders
Interventions
Per-oral Endoscopic Myotomy, Speedboat (Bipolar electrocautery knife)
Procedure · Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1Phase 2 Interventional

A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese

NCT01289288
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Mailed printed materials and in-office training
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
50 Years to 74 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated No phase listed Observational

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

NCT03165188
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 25, 2026, 6:15 AM EDT
Not listed No phase listed Observational

Mucosal Impedance Sleeve Gastrectomy

NCT04166461
View directory record Official record
Conditions
Gastroesophageal Reflux, Bariatric Surgery Candidate
Interventions
Not application, observational study
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

NAFLD Clinical Care Pathway

NCT06671886
View directory record Official record
Conditions
NAFLD, MASLD
Interventions
E-trigger
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

NCT02367183
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 25, 2026, 6:15 AM EDT
Recruiting Phase 3 Interventional

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Not applicable Interventional

High-Resolution Anoscopy Perceived Discomfort Study

NCT04083053
View directory record Official record
Conditions
Pain, Anal Cancer
Interventions
Perianal Exam, high-resolution anoscopy (HRA) with biopsy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 25, 2026, 6:15 AM EDT